Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725774 | 1.00 | LAP3 (0.44) | LAP3SLC7A5CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29761142 | 0.88 | LAP3 (0.35) | LAP3SLC7A5CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29761133 | 0.88 | DPP4 (0.36) | LAP3SLC7A5CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1758772 | 0.84 | LAP3 (0.46) | LAP3SLC7A5DPP4FAPDPP8 | |
| SCHEMBL3722214 | 0.84 | SLC7A5 (0.42) | LAP3SLC7A5DPP4FAPDPP8 | |
| SCHEMBL19347953 | 0.82 | LAP3 (0.37) | LAP3CYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL28364307 | 0.82 | LAP3 (0.37) | LAP3CYP2D6CYP2C9CYP2C19ANPEP | |
| SCHEMBL2785568 | 0.73 | SLC7A5 (0.55) | LAP3SLC7A5DPP4FAPDPP8 | |
| SCHEMBL7074325 | 0.72 | MMP2 (0.31) | CA4 | |
| SCHEMBL6551193 | 0.72 | LAP3 (0.48) | LAP3SLC7A5CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015009897-A1 | COMPOSITIONS AND METHODS FOR PRESERVING RED BLOOD CELLS AND PLATELETS | RYTHRX THERAPEUTICS, LLC (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20100093609-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TSRL, INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2008121941-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TSRL, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093609-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TYMP, SLC1A5, TYMS | LAP3 637/4885SLC7A5 19/4885CYP2D6 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.